38 research outputs found
Π‘ΠΠΠ ΠΠΠΠΠΠΠ ΠΠ ΠΠΠ‘Π’ΠΠΠΠΠΠΠ Π Π ΠΠΠ ΠΠΠ‘Π’ΠΠΠ’ΠΠΠ¬ΠΠΠΠ ΠΠΠΠ£Π¦ΠΠ ΠΠΠΠΠΠΠΠ ΠΠΠΠΠΠΠ€ΠΠΠΠΠΠΠΠΠΠΠ Π ΠΠ ΠΠ¦ΠΠ‘Π‘Π ΠΠΠ’ΠΠ‘Π’ΠΠΠΠ ΠΠΠΠΠΠ―
The article presents an overview of theΒ literature on theΒ studyΒ of theΒ mechanisms of formation ofΒ intratumoral andΒ peritumoral lymphaticΒ vesselsΒ in cancerΒ andΒ theirΒ role in regionalΒ andΒ distant metastasis.Β Lymphangiogenesis complexΒ multifactorial process, the study of which helps to clarify the overall flow pattern of the tumorΒ process.Π ΡΡΠ°ΡΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ ΠΎΠ±Π·ΠΎΡ Π΄Π°Π½Π½ΡΡ
Β Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡΒ ΠΏΠΎ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡΒ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΠΎΠ² ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ ΠΈΠ½ΡΡΠ°ΡΡΠΌΠΎΡΠ°Π»ΡΠ½ΡΡ
ΠΈ ΠΏΠ΅ΡΠΈΡΡΠΌΠΎΡΠ°Π»ΡΠ½ΡΡ
Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΎΡΡΠ΄ΠΎΠ²Β ΠΏΡΠΈ ΡΠ°ΠΊΠ΅,Β ΠΈΡ
ΡΠΎΠ»ΠΈΒ Π² ΡΠ΅Π³ΠΈΠΎΠ½Π°ΡΠ½ΠΎΠΌ ΠΈ ΠΎΡΠ΄Π°Π»Π΅Π½Π½ΠΎΠΌ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ. ΠΠΈΠΌΡΠ°Π½Π³ΠΈΠΎΠ³Π΅Π½Π΅Π· ΡΠ»ΠΎΠΆΠ½ΡΠΉ ΠΌΠ½ΠΎΠ³ΠΎΡΠ°ΠΊΡΠΎΡΠ½ΡΠΉ ΠΏΡΠΎΡΠ΅ΡΡ, ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΠΊΠΎΡΠΎΡΠΎΠ³ΠΎΒ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΡΡΠΎΡΠ½ΠΈΡΡ ΠΎΠ±ΡΡΡ ΠΊΠ°ΡΡΠΈΠ½Ρ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ°
Peritoneal Canceromatosis in Malignant Tumors of Various Localizations. Achievements and Prospects
Peritoneal carcinomatosis is viewed by many experts as a terminal illness with an unfavourable course and prognosis. Existing therapies are controversial and exhibit ambiguous efficacy. We review the current state of the art in therapy for peritoneal metastases of various origin and its historical background. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy compound the treatment of choice as achieving the highest survival rates. Palliative surgery and systemic chemotherapy are an alternative that proved even more aggressive and ineffective in comparative survival evaluations. Manifold studies and expert opinions exist on the efficacy and expedience of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treatment of peritoneal carcinomatosis. Today, however, their routine use in everyday practice is hotly debated. Despite an evident progress in managing peritoneal metastases, a series of questions remain unsolved. Contentious research data, late diagnosis, low treatment efficacy in severe peritoneal dissemination, a limited applicability of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, all highlight the importance of inventing and developing novel methods for early high-accuracy diagnosis and careful selection of the treatment strategy. Fundamental knowledge of malignant metastasis underlies the choice of patient management and the innovative toolkit for prevention and treatment of peritoneal carcinomatosis
Peritoneal Carcinomatosis: Current State of the Art and Schools of Thought
Peritoneal carcinomatosis (PC) is a global challenge of modern oncology representing the most unfavourable scenario in diverse-locality tumourisation. Despite certain attention by the oncological community, the management of PC patients is currently palliative, which weakly promotes research into the basic principles of this morbidity. This literature review attempts to comprehensively cover the PC problematic from a global perspective and presents a key evidence on the world schools of thought in this area. Briefly taking, peritoneal carcinomatosis is viewed today as a local process in the conventional implantation theory, which imposes a locoregional character on all current or emerging therapies, such as cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Their inadequate efficacy is largely due to pronounced gaps in our understanding of PC logistics and signalling. PSOGI is a key organisation for centralising the specialty effort in peritoneal carcinomatosis. Despite its global geography and approach to PC discussion, a multitude of scientific questions remain unanswered impeding the establishment of novel effective therapies. The seven countries that nurtured distinguished schools of thought in PC studies are the USA, UK, Japan, China, Italy, France and Germany. Taking peritoneal carcinomatosis in a global perspective, an insufficient attention to its problematic in Russia should be addressed. The founding and fostering of national PC institutions will benefit cancer patients and progress in oncological science
Neuroendocrine Breast Cancer. Clinical Observation. Personalized Approach
Introduction. Neuroendocrine breast tumors represent a rare subtype of breast cancer, accounting for less than 1 % of all neuroendocrine neoplasms. Starting from their pathology definition, and going through their prevalence, prognosis and treatment, our knowledge is still really uncertain.Materials and methods. The article presents a rare clinical observation of a neuroendocrine breast tumor. A breast fibroadenoma was diagnosed at the initial diagnosis stage in a private clinic; after a surgical treatment and further morphological study, it was estimated: a diagnosis of Cancer in situ of the left breast T1N0M0, stage I. Next, 3D-conformal remote radiation therapy was performed on the area of the left breast.Results and discussion. After conducting positron emission tomography, multiple metastases were detected in the lymph nodes, bones, and liver. Additionally, micropreparations were consulted at the Federal Reference Center in St. Petersburg and at an independent third-party molecular biological laboratory in Germany (Munich). Given all the instrumental, molecular biological, histological and immunohistochemical studies of the patient, an individual regimen of drug therapy was selected.Conclusion. After 18 months of personalized drug therapy, we observed a positive trend and a significant decrease in metabolic activity according to positron emission tomography
Antitumour Activity of Dehydroxymethylepoxyquinomycin (DHMEQ): a Literature Review
Carcinogenesis research uncovers new pathogenesis links as vulnerable targets of effective antitumour therapies. Among the key mediators of immune response, cell proliferation, cell apoptosis and inflammation is transcription factor NF-ΞΊB. Misregulation of an NF-ΞΊB-dependent pathway is found in solid and haematopoietic tumour cells. One of the best known NF-ΞΊB functions is expression regulation of genes involved in the apoptosis inhibition or activation and survival in both intact and malignant cells. The NF-ΞΊB-mediated pathwaysβ involvement in carcinogenesis, angiogenesis and tumour resistance to chemo- and radiotherapies makes this factor a promising target for drug anti-cancer interventions. This review summarises evidence on the antitumour and anti-inflammatory activity of a high-potent and specific low molecular-weight NF-ΞΊB inhibitor, dehydroxymethylhepoxyquinomycin (DHMEQ), as a candidate therapeutic agent in treatment for variant malignancies
ΠΠ΅ΠΉΡΠΎΡΠ½Π΄ΠΎΠΊΡΠΈΠ½Π½ΡΠΉ ΡΠ°ΠΊ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠ΅. ΠΠ½Π΄ΠΈΠ²ΠΈΠ΄ΡΠ°Π»ΡΠ½ΡΠΉ ΠΏΠΎΠ΄Ρ ΠΎΠ΄
Introduction. Neuroendocrine breast tumors represent a rare subtype of breast cancer, accounting for less than 1 % of all neuroendocrine neoplasms. Starting from their pathology definition, and going through their prevalence, prognosis and treatment, our knowledge is still really uncertain.Materials and methods. The article presents a rare clinical observation of a neuroendocrine breast tumor. A breast fibroadenoma was diagnosed at the initial diagnosis stage in a private clinic; after a surgical treatment and further morphological study, it was estimated: a diagnosis of Cancer in situ of the left breast T1N0M0, stage I. Next, 3D-conformal remote radiation therapy was performed on the area of the left breast.Results and discussion. After conducting positron emission tomography, multiple metastases were detected in the lymph nodes, bones, and liver. Additionally, micropreparations were consulted at the Federal Reference Center in St. Petersburg and at an independent third-party molecular biological laboratory in Germany (Munich). Given all the instrumental, molecular biological, histological and immunohistochemical studies of the patient, an individual regimen of drug therapy was selected.Conclusion. After 18 months of personalized drug therapy, we observed a positive trend and a significant decrease in metabolic activity according to positron emission tomography.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠΠ΅ΠΉΡΠΎΡΠ½Π΄ΠΎΠΊΡΠΈΠ½Π½ΡΠ΅ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΡΡ ΡΠΎΠ±ΠΎΠΉ ΡΠ΅Π΄ΠΊΠΈΠΉ ΠΏΠΎΠ΄ΡΠΈΠΏ ΡΠ°ΠΊΠ° ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, ΡΠΎΡΡΠ°Π²Π»ΡΡ ΠΌΠ΅Π½Π΅Π΅ 1 % Π²ΡΠ΅Ρ
Π½Π΅ΠΉΡΠΎΡΠ½Π΄ΠΎΠΊΡΠΈΠ½Π½ΡΡ
Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ. ΠΡΡ
ΠΎΠ΄Ρ ΠΈΠ· ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ, ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΠΈ, ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ, Π½Π°ΡΠΈ Π·Π½Π°Π½ΠΈΡ Π²ΡΠ΅ Π΅ΡΠ΅ ΠΎΡΡΠ°ΡΡΡΡ Π½Π΅ΠΎΡΠΎΡΠΌΠ»Π΅Π½Π½ΡΠΌΠΈ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΡΡΠ°ΡΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ΠΎ ΡΠ΅Π΄ΠΊΠΎΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠ΅ Π½Π΅ΠΉΡΠΎΡΠ½Π΄ΠΎΠΊΡΠΈΠ½Π½ΠΎΠΉ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. Π€ΠΈΠ±ΡΠΎΠ°Π΄Π΅Π½ΠΎΠΌΠ° ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠΎΠ²Π°Π½Π° Π½Π° Π½Π°ΡΠ°Π»ΡΠ½ΠΎΠΌ ΡΡΠ°ΠΏΠ΅ Π² ΡΠ°ΡΡΠ½ΠΎΠΉ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠ΅. ΠΠΎΡΠ»Π΅ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠ΅Π³ΠΎ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π±ΡΠ»ΠΎ ΠΎΡΠ΅Π½Π΅Π½ΠΎ: Π΄ΠΈΠ°Π³Π½ΠΎΠ· Β«Π Π°ΠΊ in situΒ» Π»Π΅Π²ΠΎΠΉ Π³ΡΡΠ΄ΠΈ T1N0M0, I ΡΡΠ°Π΄ΠΈΡ. ΠΠ°ΡΠ΅ΠΌ Π±ΡΠ»Π° ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π° 3D-ΠΊΠΎΠ½ΡΠΎΡΠΌΠ½Π°Ρ Π΄ΠΈΡΡΠ°Π½ΡΠΈΠΎΠ½Π½Π°Ρ Π»ΡΡΠ΅Π²Π°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ Π² ΠΎΠ±Π»Π°ΡΡΠΈ Π»Π΅Π²ΠΎΠΉ Π³ΡΡΠ΄ΠΈ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈ ΠΎΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠ΅. ΠΠΎΡΠ»Π΅ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ ΠΏΠΎΠ·ΠΈΡΡΠΎΠ½Π½ΠΎ-ΡΠΌΠΈΡΡΠΈΠΎΠ½Π½ΠΎΠΉ ΡΠΎΠΌΠΎΠ³ΡΠ°ΡΠΈΠΈ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Ρ ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²Π΅Π½Π½ΡΠ΅ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·Ρ Π² Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ·Π»Π°Ρ
, ΠΊΠΎΡΡΡΡ
ΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΈ. ΠΡΠΎΠΌΠ΅ ΡΠΎΠ³ΠΎ, ΠΏΠΎ ΠΌΠΈΠΊΡΠΎΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌ ΠΊΠΎΠ½ΡΡΠ»ΡΡΠΈΡΠΎΠ²Π°Π»ΠΈΡΡ Π² Π€Π΅Π΄Π΅ΡΠ°Π»ΡΠ½ΠΎΠΌ ΡΠΏΡΠ°Π²ΠΎΡΠ½ΠΎΠΌ ΡΠ΅Π½ΡΡΠ΅ Π² Π‘Π°Π½ΠΊΡ-ΠΠ΅ΡΠ΅ΡΠ±ΡΡΠ³Π΅ ΠΈ Π² Π½Π΅Π·Π°Π²ΠΈΡΠΈΠΌΠΎΠΉ ΡΡΠΎΡΠΎΠ½Π½Π΅ΠΉ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎ-Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠΈΠΈ Π² ΠΠ΅ΡΠΌΠ°Π½ΠΈΠΈ (ΠΡΠ½Ρ
Π΅Π½). Π£ΡΠΈΡΡΠ²Π°Ρ Π²ΡΠ΅ ΠΈΠ½ΡΡΡΡΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΡΠ΅, ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎ-Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅, Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°, Π±ΡΠ»Π° ΠΏΠΎΠ΄ΠΎΠ±ΡΠ°Π½Π° ΠΈΠ½Π΄ΠΈΠ²ΠΈΠ΄ΡΠ°Π»ΡΠ½Π°Ρ ΡΡ
Π΅ΠΌΠ° ΠΌΠ΅Π΄ΠΈΠΊΠ°ΠΌΠ΅Π½ΡΠΎΠ·Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠΎΡΠ»Π΅ 18 ΠΌΠ΅ΡΡΡΠ΅Π² ΠΈΠ½Π΄ΠΈΠ²ΠΈΠ΄ΡΠ°Π»ΡΠ½ΠΎΠΉ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΌΡ Π½Π°Π±Π»ΡΠ΄Π°Π»ΠΈ ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΡΡ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΡ ΠΈ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠ΅ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΏΠΎ Π΄Π°Π½Π½ΡΠΌ ΠΏΠΎΠ·ΠΈΡΡΠΎΠ½Π½ΠΎ-ΡΠΌΠΈΡΡΠΈΠΎΠ½Π½ΠΎΠΉ ΡΠΎΠΌΠΎΠ³ΡΠ°ΡΠΈΠΈ
Π€ΠΠΠ’ΠΠ Π« ΠΠ ΠΠΠΠΠ¦ΠΠ ΠΠ Π Π ΠΠΠ ΠΠΠΠΠ§ΠΠΠ ΠΠΠΠΠΠ«
The article presents the results of the study depending survival of patients with breast cancer (BC) stage IIIb degree from neolymphangiogenesis . The results show that the higher the degree neolymphangiogenesis on the level lymphangion at the drainage area βsentinelβ lymphΒ node, theΒ moreΒ pronounced local compensatory andΒ protective reactions ofΒ the organism affecting the duration of life in breast cancer.Π ΡΡΠ°ΡΡΠ΅Β ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡΒ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈΒ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ ΠΏΡΠΈ ΡΠ°ΠΊΠ΅Β ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·ΡΒ (Π ΠΠ) IIIΠ± ΡΡΠ°Π΄ΠΈΠΈΒ ΠΎΡ ΡΡΠ΅ΠΏΠ΅Π½ΠΈΒ Π½Π΅ΠΎΠ»ΠΈΠΌΡΠ°Π½Π³ΠΈΠΎΠ³Π΅Π½Π΅Π·Π°.Β ΠΠ°Π½Π½ΡΠ΅Β ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΡΡ ΠΎ ΡΠΎΠΌ,Β ΡΡΠΎ ΡΠ΅ΠΌΒ Π²ΡΡΠ΅Β ΡΡΠ΅ΠΏΠ΅Π½ΡΒ Π½Π΅ΠΎΠ»ΠΈΠΌΡΠ°Π½Π³ΠΈΠΎΠ³Π΅Π½Π΅Π·Π° Π½Π° ΡΡΠΎΠ²Π½Π΅Β Π»ΠΈΠΌΡΠ°Π½Π³ΠΈΠΎΠ½Π° Π² Π±Π°ΡΡΠ΅ΠΉΠ½Π΅ Β«ΡΡΠΎΡΠΎΠΆΠ΅Π²ΠΎΠ³ΠΎΒ» Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ·Π»Π°,Β ΡΠ΅ΠΌ Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠ°ΠΆΠ΅Π½Ρ ΠΌΠ΅ΡΡΠ½ΡΠ΅ ΠΊΠΎΠΌΠΏΠ΅Π½ΡΠ°ΡΠΎΡΠ½ΠΎ-Π·Π°ΡΠΈΡΠ½ΡΠ΅ ΡΠ΅Π°ΠΊΡΠΈΠΈ ΠΎΡΠ³Π°Π½ΠΈΠ·ΠΌΠ°, Π²Π»ΠΈΡΡΡΠΈΠ΅ Π½Π° ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΆΠΈΠ·Π½ΠΈ ΠΏΡΠΈ ΡΠ°ΠΊΠ΅ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ.
ΠΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ ΠΎΠ»Π΅Π²Π°Ρ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ Π΄Π΅Π³ΠΈΠ΄ΡΠΎΠΊΡΠΈΠΌΠ΅ΡΠΈΠ»ΡΠΏΠΎΠΊΡΠΈΡ ΠΈΠ½ΠΎΠΌΠΈΡΠΈΠ½Π° (DHMEQ) ΠΈ ΡΠΈΡΠΏΠ»Π°ΡΠΈΠ½Π° Π½Π° ΠΌΠΎΠ΄Π΅Π»ΠΈ Π΄ΠΈΡΡΠ΅ΠΌΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΠ°ΠΊΠ° ΡΠΈΡΠ½ΠΈΠΊΠΎΠ²
Introduction. Ovarian cancer (OC) is recognized to be a pressing problem of modern oncology. Cytoreductive surgery and combined therapy based on platinum and taxanes play an important role in OC treatment. The response rate to first-line therapy accounts for about 80β90%. However, most patients relapse and develop resistance to therapy. Thus, the search for new effective drugs and new combinations for OC treatment is an urgent task of modern oncology.Aim. To evaluate in vivo the antitumor activity of dehydroxymethylepoxyquinomycin (DHMEQ) and cisplatin combination in an ovarian cancer model.Materials and methods. An experimental model of disseminated OC in rats was used to evaluate antitumor activity. A strain of ovarian tumor (OT) was transplanted into 200 female Wistar rats. The drugs were administered intraperitoneally. The βmedian life expectancyβ was taken as a benchmark for the quality evaluation of experimental treatment.Results. It was found that DHMEQ and cisplatin combination increased the survival rate by 387% (p = 0.005, log-rank test) compared to the control group and by 91% compared to the group of animals treated with cisplatin (p = 0.003, log-rank test) in mono mode. More than 50% of the animals in the DHMEQ + cisplatin group remained alive on day 73 of the experiment. No animals remained alive in the cisplatin group, and only one rat remained in the DHMEQ group.Discussion. Thus, the obtained data demonstrate a potentiating antitumor effect of the DHMEQ + cisplatin combination by 387% compared to the control group.Conclusion. The results of the experiments demonstrated a potentiating antitumor effect of DHMEQ in combination with cisplatin. DHMEQ in combination with cisplatin manifests high efficacy in an in vivo model of ovarian cancer.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. Π Π°ΠΊ ΡΠΈΡΠ½ΠΈΠΊΠΎΠ² (Π Π―) ΡΠ²Π»ΡΠ΅ΡΡΡ Π°ΠΊΡΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠΎΠΉ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΉ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΠΈ. Π Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Π Π― Π²Π°ΠΆΠ½ΡΡ ΡΠΎΠ»Ρ ΠΈΠ³ΡΠ°Π΅Ρ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ ΡΠΈΡΠΎΡΠ΅Π΄ΡΠΊΡΠΈΠ²Π½ΠΎΠΉ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ ΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌΠΈ ΠΏΠ»Π°ΡΠΈΠ½Ρ ΠΈ ΡΠ°ΠΊΡΠ°Π½Π°ΠΌΠΈ. Π§Π°ΡΡΠΎΡΠ° ΠΎΡΠ²Π΅ΡΠ° Π½Π° ΡΠ΅ΡΠ°ΠΏΠΈΡ ΠΏΠ΅ΡΠ²ΠΎΠΉ Π»ΠΈΠ½ΠΈΠΈ ΡΠΎΡΡΠ°Π²Π»ΡΠ΅Ρ ΠΎΠΊΠΎΠ»ΠΎ 80β90 %, Π½ΠΎ Ρ Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π²ΠΎΠ·Π½ΠΈΠΊΠ°Π΅Ρ ΡΠ΅ΡΠΈΠ΄ΠΈΠ² ΠΈ ΡΠ°Π·Π²ΠΈΠ²Π°Π΅ΡΡΡ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΡ ΠΊ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ. Π’Π°ΠΊΠΈΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠΌ, ΠΏΠΎΠΈΡΠΊ Π½ΠΎΠ²ΡΡ
ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
ΡΡΠ΅Π΄ΡΡΠ² ΠΈ Π½ΠΎΠ²ΡΡ
ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΉ Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ Π Π― ΡΠ²Π»ΡΠ΅ΡΡΡ Π°ΠΊΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π·Π°Π΄Π°ΡΠ΅ΠΉ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΉ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΠΈ.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ. Π ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ΅ in vivo ΠΎΡΠ΅Π½ΠΈΡΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ Π΄Π΅Π³ΠΈΠ΄ΡΠΎΠΊΡΠΈΠΌΠ΅ΡΠΈΠ»ΡΠΏΠΎΠΊΡΠΈΡ
ΠΈΠ½ΠΎΠΌΠΈΡΠΈΠ½Π° (DHMEQ) ΠΈ ΡΠΈΡΠΏΠ»Π°ΡΠΈΠ½Π° Π½Π° ΠΌΠΎΠ΄Π΅Π»ΠΈ ΡΠ°ΠΊΠ° ΡΠΈΡΠ½ΠΈΠΊΠΎΠ².ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠ»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΡΡ ΠΌΠΎΠ΄Π΅Π»Ρ Π΄ΠΈΡΡΠ΅ΠΌΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ Π Π― Ρ ΠΊΡΡΡ. ΠΡΠ»ΠΎ ΠΎΡΠΎΠ±ΡΠ°Π½ΠΎ 200 ΠΊΡΡΡ-ΡΠ°ΠΌΠΎΠΊ ΠΠΈΡΡΠ°Ρ, ΠΊΠΎΡΠΎΡΡΠΌ ΠΏΠ΅ΡΠ΅Π²ΠΈΠ²Π°Π»ΡΡ ΡΡΠ°ΠΌΠΌ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΡΠΈΡΠ½ΠΈΠΊΠΎΠ² (ΠΠ―). ΠΡΠ΅ΠΏΠ°ΡΠ°ΡΡ Π²Π²ΠΎΠ΄ΠΈΠ»ΠΈΡΡ Π²Π½ΡΡΡΠΈΠ±ΡΡΡΠΈΠ½Π½ΠΎ. ΠΡΠΈΠ΅Π½ΡΠΈΡΠΎΠΌ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΡΠΈΠ½ΠΈΠΌΠ°Π»ΠΈ ΠΌΠ΅Π΄ΠΈΠ°Π½Ρ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ ΠΆΠΈΠ·Π½ΠΈ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΡΠ»ΠΎ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΎ, ΡΡΠΎ ΠΏΡΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ DHMEQ Ρ ΡΠΈΡΠΏΠ»Π°ΡΠΈΠ½ΠΎΠΌ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΎ 387 % (p = 0,005, log-rank test) ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΠΎΠΉ ΠΈ Π½Π° 91 % ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ Π³ΡΡΠΏΠΏΠΎΠΉ ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ
, ΠΊΠΎΡΠΎΡΡΠΌ Π±ΡΠ» Π²Π²Π΅Π΄Π΅Π½ ΡΠΈΡΠΏΠ»Π°ΡΠΈΠ½ (p = 0,003, log-rank test) Π² ΠΌΠΎΠ½ΠΎΡΠ΅ΠΆΠΈΠΌΠ΅. ΠΠΎΠ»Π΅Π΅ 50 % ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ
Π² Π³ΡΡΠΏΠΏΠ΅ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ DHMEQ + ΡΠΈΡΠΏΠ»Π°ΡΠΈΠ½ ΠΎΡΡΠ°Π²Π°Π»ΠΈΡΡ ΠΆΠΈΠ²ΡΠΌΠΈ Π½Π° 73 ΡΡΡΠΊΠΈ ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°. Π Π³ΡΡΠΏΠΏΠ΅ Ρ ΡΠΈΡΠΏΠ»Π°ΡΠΈΠ½ΠΎΠΌ Π½Π΅ ΠΎΡΡΠ°Π»ΠΎΡΡ Π½ΠΈ ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΆΠΈΠ²ΠΎΡΠ½ΠΎΠ³ΠΎ, Π° Π² Π³ΡΡΠΏΠΏΠ΅ Ρ DHMEQ Π² ΠΆΠΈΠ²ΡΡ
ΠΎΡΡΠ°Π²Π°Π»ΠΎΡΡ Π»ΠΈΡΡ ΠΎΠ΄Π½Π° ΠΊΡΡΡΠ°. ΠΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠ΅. Π’Π°ΠΊΠΈΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠΌ, Π±ΡΠ»ΠΈ ΠΏΠΎΠ»ΡΡΠ΅Π½Ρ Π΄Π°Π½Π½ΡΠ΅, Π΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΡΡΡΠΈΠ΅ ΠΏΠΎΡΠ΅Π½ΡΠΈΡΡΡΡΠΈΠΉ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΠΉ ΡΡΡΠ΅ΠΊΡ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ DHMEQ Ρ ΡΠΈΡΠΏΠ»Π°ΡΠΈΠ½ΠΎΠΌ Π½Π° 387 % ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΠΎΠΉ.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ΅ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΡΡ
ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠΎΠ² Π±ΡΠ»ΠΈ ΠΏΠΎΠ»ΡΡΠ΅Π½Ρ Π΄Π°Π½Π½ΡΠ΅, Π΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΡΡΡΠΈΠ΅ ΠΏΠΎΡΠ΅Π½ΡΠΈΡΡΡΡΠΈΠΉ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΠΉ ΡΡΡΠ΅ΠΊΡ DHMEQ Π² ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ Ρ ΡΠΈΡΠΏΠ»Π°ΡΠΈΠ½ΠΎΠΌ. ΠΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΡΠ°ΠΊΠΆΠ΅ Π΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΡΡΡ, ΡΡΠΎ DHMEQ Π² ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ Ρ ΡΠΈΡΠΏΠ»Π°ΡΠΈΠ½ΠΎΠΌ ΠΏΡΠΎΡΠ²Π»ΡΠ΅Ρ Π²ΡΡΠΎΠΊΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π½Π° in vivo ΠΌΠΎΠ΄Π΅Π»ΠΈ ΡΠ°ΠΊΠ° ΡΠΈΡΠ½ΠΈΠΊΠΎΠ²
ΠΠ΅ΠΎΠ»ΠΈΠΌΡΠΎΠ³Π΅Π½Π΅Π· ΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠ·Π»ΠΎΠ² ΠΏΡΠΈ ΡΠ°ΠΊΠ΅ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ
Background. Our previous studies have shown that postnatally formed lymph nodes (PNFLN) can serve as a source of biological signals activating antitumour immune reactions and suppressing the spread of metastatic malignant cells.Aim. To determine the expression of CD3, CD20, CD68 in native, sentinel and postnatally induced lymph nodes of the axillary zone in breast cancer.Materials and methods. The study involved an analysis of digitalized images of the immunohistochemical expression of a fixed panel of antibodies CD3, CD20, CD68. The expression levels were assessed quantitatively by counting the expressed cells in each studied node for four main structural and functional zones.Results and Discussion. The results of a comparative immunohistochemical study of native, sentinel and postnatally induced lymph nodes showed that the content of CD3, CD20, CD68 demonstrates fundamental differences in different lymph node structures.Π‘onclusions 1. In postnatally induced lymph nodes, compared to native and sentinel lymph nodes, the distinct expression of antibodies to the main immunocompetent cells, which realize key immune responses in the lymph node, can indicate an increased functional status of the newly formed lymph nodes. 2. The study demonstrated a high level of antigenic stimulation of T and B lymphocytes in postnatally induced lymph nodes, as well as indicated a possible role of macrophage cells in the stimulation of neolymphogenesis and the formation of new lymph nodes. 3. The study provides the basis for further research into postnatal induced lymph nodes in cancer patients.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. Π Π°Π½Π΅Π΅ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΡΠ΅ Π½Π°ΠΌΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π΄ΠΎΠΊΠ°Π·Π°Π»ΠΈ, ΡΡΠΎ ΠΏΠΎΡΡΠ½Π°ΡΠ°Π»ΡΠ½ΠΎ ΡΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ·Π»Ρ ΠΌΠΎΠ³ΡΡ ΡΠ»ΡΠΆΠΈΡΡ ΠΈΡΡΠΎΡΠ½ΠΈΠΊΠΎΠΌ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΈΠ³Π½Π°Π»ΠΎΠ², Π°ΠΊΡΠΈΠ²ΠΈΡΡΡΡΠΈΡ
ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΠ΅ ΡΠ΅Π°ΠΊΡΠΈΠΈ ΠΈΠΌΠΌΡΠ½ΠΈΡΠ΅ΡΠ° ΠΈ ΠΏΠΎΠ΄Π°Π²Π»ΡΡΡΠΈΡ
ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΠ΅ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΈΡΡΡΡΠΈΡ
Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ.Π¦Π΅Π»Ρ ΡΠ°Π±ΠΎΡΡ: ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ CD3, CD20, CD68 Π² Π½Π°ΡΠΈΠ²Π½ΡΡ
, ΡΡΠΎΡΠΎΠΆΠ΅Π²ΡΡ
ΠΈ ΠΏΠΎΡΡΠ½Π°ΡΠ°Π»ΡΠ½ΠΎ ΠΈΠ½Π΄ΡΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ·Π»Π°Ρ
Π°ΠΊΡΠΈΠ»Π»ΡΡΠ½ΠΎΠΉ Π·ΠΎΠ½Ρ ΠΏΡΠΈ ΡΠ°ΠΊΠ΅ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΠΎΠ΄Π²Π΅ΡΠ³Π°Π»ΠΈΡΡ Π³ΠΎΡΠΎΠ²ΡΠ΅ ΠΎΡΠΈΡΡΠΎΠ²Π°Π½Π½ΡΠ΅ ΠΈΠ·ΠΎΠ±ΡΠ°ΠΆΠ΅Π½ΠΈΡ ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΡΠΈΠΊΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΏΠ°Π½Π΅Π»ΠΈ Π°Π½ΡΠΈΡΠ΅Π» CD3, CD20, CD68. ΠΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ ΠΎΡΠ΅Π½ΠΊΡ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΏΠΎΠ΄ΡΡΠ΅ΡΠ° ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ Π² ΠΊΠ°ΠΆΠ΄ΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½ΠΎΠΌ ΡΠ·Π»Π΅ ΠΏΠΎ ΡΠ΅ΡΡΡΠ΅ΠΌ ΠΎΡΠ½ΠΎΠ²Π½ΡΠΌ ΡΡΡΡΠΊΡΡΡΠ½ΠΎ-ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠΌ Π·ΠΎΠ½Π°ΠΌ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈ ΠΎΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠ΅. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π½Π°ΡΠΈΠ²Π½ΡΡ
, ΡΡΠΎΡΠΎΠΆΠ΅Π²ΡΡ
ΠΈ ΠΏΠΎΡΡΠ½Π°ΡΠ°Π»ΡΠ½ΠΎ ΠΈΠ½Π΄ΡΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ·Π»ΠΎΠ² ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΈ, ΡΡΠΎ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ CD3, CD20, CD68 Π² ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΡΡΡΡΠΊΡΡΡΠ°Ρ
Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ·Π»ΠΎΠ² ΠΈΠΌΠ΅Π»ΠΎ ΠΏΡΠΈΠ½ΡΠΈΠΏΠΈΠ°Π»ΡΠ½ΡΠ΅ ΠΎΡΠ»ΠΈΡΠΈΡ.ΠΡΠ²ΠΎΠ΄Ρ 1. Π ΠΏΠΎΡΡΠ½Π°ΡΠ°Π»ΡΠ½ΠΎ ΠΈΠ½Π΄ΡΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ·Π»Π°Ρ
ΠΎΡΡΠ΅ΡΠ»ΠΈΠ²ΠΎ Π²ΡΡΠ²Π»Π΅Π½Π° ΠΎΡΠ»ΠΈΡΠ½Π°Ρ ΠΎΡ Π½Π°ΡΠΈΠ²Π½ΡΡ
ΠΈ ΡΡΠΎΡΠΎΠΆΠ΅Π²ΡΡ
Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ·Π»ΠΎΠ² ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ Π°Π½ΡΠΈΡΠ΅Π» ΠΊ ΠΎΡΠ½ΠΎΠ²Π½ΡΠΌ ΠΈΠΌΠΌΡΠ½ΠΎΠΊΠΎΠΌΠΏΠ΅ΡΠ΅Π½ΡΠ½ΡΠΌ ΠΊΠ»Π΅ΡΠΊΠ°ΠΌ, ΡΠ΅Π°Π»ΠΈΠ·ΡΡΡΠΈΡ
Π² Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΌ ΡΠ·Π»Π΅ ΠΊΠ»ΡΡΠ΅Π²ΡΠ΅ ΠΈΠΌΠΌΡΠ½Π½ΡΠ΅ ΡΠ΅Π°ΠΊΡΠΈΠΈ, ΡΡΠΎ ΠΌΠΎΠΆΠ΅Ρ ΡΠΊΠ°Π·ΡΠ²Π°ΡΡ Π½Π° ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΡΠΉ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠΉ ΡΡΠ°ΡΡΡ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½Π½ΡΡ
Π»ΠΈΠΌΡΠΎΡΠ·Π»ΠΎΠ². 2. ΠΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΡΠ΅Ρ Π²ΡΡΠΎΠΊΠΈΠΉ ΡΡΠΎΠ²Π΅Π½Ρ Π°Π½ΡΠΈΠ³Π΅Π½Π½ΠΎΠΉ ΡΡΠΈΠΌΡΠ»ΡΡΠΈΠΈ Π’- ΠΈ Π-Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² Π² ΠΠΠΠΠ£, Π° ΡΠ°ΠΊΠΆΠ΅ ΡΠΊΠ°Π·ΡΠ²Π°Π΅Ρ Π½Π° Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΡΡ ΡΠΎΠ»Ρ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΌΠ°ΠΊΡΠΎΡΠ°Π³Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ΄Π° Π² ΡΡΠΈΠΌΡΠ»ΡΡΠΈΠΈ Π½Π΅ΠΎΠ»ΠΈΠΌΡΠΎΠ³Π΅Π½Π΅Π·Π° ΠΈ ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ Π½ΠΎΠ²ΡΡ
Π»ΠΈΠΌΡΠΎΡΠ·Π»ΠΎΠ². 3. Π Π΅Π°Π»ΠΈΠ·Π°ΡΠΈΡ Π΄Π°Π½Π½ΠΎΠ³ΠΎ Π½Π°ΡΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠΎΠ΅ΠΊΡΠ° ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ Π² Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠΈΡ
Π½Π°ΡΡΠ½ΡΡ
ΠΈΠ·ΡΡΠΊΠ°Π½ΠΈΡΡ
Π·Π°Π»ΠΎΠΆΠΈΡΡ ΡΡΠ½Π΄Π°ΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΡΠ΅ ΠΎΡΠ½ΠΎΠ²Ρ Π΄Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ, ΠΏΠΎΡΠ²ΡΡΠ΅Π½Π½ΡΡ
ΠΏΠΎΡΡΠ½Π°ΡΠ°Π»ΡΠ½ΡΠΌ ΠΈΠ½Π΄ΡΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌ Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΠ·Π»Π°ΠΌ Ρ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ Π»ΠΈΠΌΡΡ ΠΈ Π΅Π΅ ΡΠ΅ΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΏΡΠΈ ΡΠ°ΠΊΠ΅ ΠΊΠ°ΠΊ ΡΠ°ΠΊΡΠΎΡ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΈΡΠΎΠ²Π°Π½ΠΈΡ (Π½Π° ΠΏΡΠΈΠΌΠ΅ΡΠ΅ ΡΠ°ΠΊΠ° ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ)
Introduction. Despite the large number of scientific studies on metastasis problems, the state of liquid media (lymph and blood) in oncological diseases remained without sufficient attention.Materials and methods. A study of the lymph fluid properties, including viscosity, of 100 female patients with malignant breast tumours was carried out. The age of the patients ranged from 50 to 80 years. All patients were in menopause. The material for determination of viscosity was taken 5β7 days following mastectomy with extended dissection of axillary lymph nodes. On the first and second days, the contents of the wound were represented by blood clots and serous fluid. Between three- and five-days following surgery, the discharge from the wound consisted of serous discharge, prelims and lymph. On the fifth day and the following days, the wound discharge consisted primarily of lymph fluid caused by the completed haemostasis and continuation of discharge from the small lymphatic vessels.Results. The metastatic process is more active during the initial stages of cancer, since the metastatic medium is represented by less viscous lymph fluid while the vessels for the most part retain their permeability. With advanced stages of cancer, when the viscosity of the lymph rises, metastasis slows down.Conclusions: (1) In breast cancer, the viscosity depends on the stage of the cancer, while the lymph in the tumour pool behaves like a non-Newtonian fluid. (2) In stages I-II of cancer, metastasis occurs more actively than in cancer at more advanced stages. This phenomenon is determined by the rheological properties of the lymph and the functional viability of the regional vascular system.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠΠ΅ΡΠΌΠΎΡΡΡ Π½Π° ΠΌΠ½ΠΎΠ³ΠΎΡΠΈΡΠ»Π΅Π½Π½ΠΎΡΡΡ Π½Π°ΡΡΠ½ΡΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΠΏΠΎ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ°ΠΌ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΈΡΠΎΠ²Π°Π½ΠΈΡ, Π²ΠΎΠΏΡΠΎΡΡ ΡΠΎΡΡΠΎΡΠ½ΠΈΡ ΠΆΠΈΠ΄ΠΊΠΈΡ
ΡΡΠ΅Π΄ (Π»ΠΈΠΌΡΡ ΠΈ ΠΊΡΠΎΠ²ΠΈ) ΠΏΡΠΈ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΡ
ΠΎΡΡΠ°Π²Π°Π»ΠΈΡΡ Π±Π΅Π· Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΠ³ΠΎ Π²Π½ΠΈΠΌΠ°Π½ΠΈΡ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠ·ΡΡΠ°Π»ΠΈΡΡ ΡΠ²ΠΎΠΉΡΡΠ²Π° Π»ΠΈΠΌΡΡ Ρ ΠΆΠ΅Π½ΡΠΈΠ½ ΡΠΎ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΌΠΈ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡΠΌΠΈ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. ΠΡΠ·ΠΊΠΎΡΡΡ Π»ΠΈΠΌΡΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π° Ρ 100 Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ°ΠΊΠΎΠΌ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. ΠΠΎΠ·ΡΠ°ΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΈΠΌΠ΅Π» Π΄ΠΈΠ°ΠΏΠ°Π·ΠΎΠ½ ΠΎΡ 50 Π΄ΠΎ 80 Π»Π΅Ρ. ΠΡΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΊΠΈ Π±ΡΠ»ΠΈ Π² ΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Π΅. ΠΠ°ΡΠ΅ΡΠΈΠ°Π» Π΄Π»Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ Π²ΡΠ·ΠΊΠΎΡΡΠΈ Π·Π°Π±ΠΈΡΠ°Π»ΡΡ Π½Π° 5β7 ΡΡΡΠΊΠΈ ΠΏΠΎΡΠ»Π΅ ΠΌΠ°ΡΡΡΠΊΡΠΎΠΌΠΈΠΈ Ρ ΡΠ°ΡΡΠΈΡΠ΅Π½Π½ΠΎΠΉ Π»ΠΈΠΌΡΠΎΠ΄ΠΈΡΡΠ΅ΠΊΡΠΈΠ΅ΠΉ Π°ΠΊΡΠΈΠ»Π»ΡΡΠ½ΡΡ
Π»ΠΈΠΌΡΠΎΡΠ·Π»ΠΎΠ². ΠΠ° ΠΏΠ΅ΡΠ²ΡΠ΅-Π²ΡΠΎΡΡΠ΅ ΡΡΡΠΊΠΈ ΡΠΎΠ΄Π΅ΡΠΆΠΈΠΌΠΎΠ΅ ΡΠ°Π½Ρ Π±ΡΠ»ΠΎ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ΠΎ ΠΊΡΠΎΠ²ΡΠ½ΡΠΌΠΈ ΡΠ³ΡΡΡΠΊΠ°ΠΌΠΈ ΠΈ ΡΠ΅ΡΠΎΠ·Π½ΠΎΠΉ ΠΆΠΈΠ΄ΠΊΠΎΡΡΡΡ. ΠΠ° 3β5 ΡΡΡΠΊΠΈ ΠΎΡΠ΄Π΅Π»ΡΠ΅ΠΌΠΎΠ΅ ΡΠ°Π½Ρ ΡΠΎΡΡΠΎΡΠ»ΠΎ ΠΈΠ· ΡΠ΅ΡΠΎΠ·Π½ΠΎΠ³ΠΎ ΠΎΡΠ΄Π΅Π»ΡΠ΅ΠΌΠΎΠ³ΠΎ, ΠΏΡΠ΅Π»ΠΈΠΌΡΡ ΠΈ Π»ΠΈΠΌΡΡ. ΠΠ° ΠΏΡΡΡΠ΅ ΡΡΡΠΊΠΈ ΠΈ ΠΏΠΎΡΠ»Π΅Π΄ΡΡΡΠΈΠ΅ Π΄Π½ΠΈ Π² ΠΎΡΠ΄Π΅Π»ΡΠ΅ΠΌΠΎΠΌ ΠΈΠ· ΡΠ°Π½Ρ ΠΏΡΠ΅Π²Π°Π»ΠΈΡΠΎΠ²Π°Π»Π° Π»ΠΈΠΌΡΠ°, ΡΡΠΎ ΠΎΠ±ΡΡΠ»ΠΎΠ²Π»Π΅Π½ΠΎ Π·Π°Π²Π΅ΡΡΠΈΠ²ΡΠΈΠΌΡΡ Π³Π΅ΠΌΠΎΡΡΠ°Π·ΠΎΠΌ ΠΈ ΡΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΠ΅ΠΌ ΠΎΡΠ΄Π΅Π»ΡΠ΅ΠΌΠΎΠ³ΠΎ ΠΈΠ· ΠΌΠ΅Π»ΠΊΠΈΡ
Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΎΡΡΠ΄ΠΎΠ².Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΏΡΠΎΡΠ΅ΡΡ ΠΏΡΠΎΡ
ΠΎΠ΄ΠΈΡ Π±ΠΎΠ»Π΅Π΅ Π°ΠΊΡΠΈΠ²Π½ΠΎ ΠΏΡΠΈ Π½Π°ΡΠ°Π»ΡΠ½ΡΡ
ΡΡΠ°Π΄ΠΈΡΡ
ΡΠ°ΠΊΠ°, ΡΠ°ΠΊ ΠΊΠ°ΠΊ ΡΡΠ΅Π΄Π° ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π° Π»ΠΈΠΌΡΠΎΠΉ ΠΌΠ΅Π½Π΅Π΅ Π²ΡΠ·ΠΊΠΎΠΉ, Π° ΡΠΎΡΡΠ΄Ρ Π² ΡΠ²ΠΎΠ΅ΠΌ Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π΅ ΡΠΎΡ
ΡΠ°Π½ΡΡΡ ΠΏΡΠΎΡ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΡ. ΠΡΠΈ ΠΏΡΠΎΠ΄Π²ΠΈΠ½ΡΡΡΡ
ΡΡΠ°Π΄ΠΈΡΡ
ΡΠ°ΠΊΠ°, ΠΊΠΎΠ³Π΄Π° ΠΏΠΎΠ²ΡΡΠ°Π΅ΡΡΡ Π²ΡΠ·ΠΊΠΎΡΡΡ Π»ΠΈΠΌΡΡ, ΠΏΡΠΎΡΠ΅ΡΡΡ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π·Π°ΠΌΠ΅Π΄Π»ΡΡΡΡΡ. ΠΡΠ²ΠΎΠ΄Ρ. 1. ΠΡΠΈ ΡΠ°ΠΊΠ΅ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ Π²ΡΠ·ΠΊΠΎΡΡΡ Π·Π°Π²ΠΈΡΠΈΡ ΠΎΡ ΡΡΠ°Π΄ΠΈΠΈ ΡΠ°ΠΊΠ°, ΠΏΡΠΈ ΡΡΠΎΠΌ Π»ΠΈΠΌΡΠ° Π² Π±Π°ΡΡΠ΅ΠΉΠ½Π΅ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ Π²Π΅Π΄Π΅Ρ ΡΠ΅Π±Ρ ΠΊΠ°ΠΊ Π½Π΅Π½ΡΡΡΠΎΠ½ΠΎΠ²ΡΠΊΠ°Ρ ΠΆΠΈΠ΄ΠΊΠΎΡΡΡ. 2. ΠΡΠΈ IβII ΡΡΠ°Π΄ΠΈΠΈ ΡΠ°ΠΊΠ° ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΡΠΎΠΈΡΡ
ΠΎΠ΄ΠΈΡ Π±ΠΎΠ»Π΅Π΅ Π°ΠΊΡΠΈΠ²Π½ΠΎ, ΡΠ΅ΠΌ ΠΏΡΠΈ ΡΠ°ΠΊΠ΅ Ρ ΠΏΡΠΎΠ΄Π²ΠΈΠ½ΡΡΡΠΌΠΈ ΡΡΠ°Π΄ΠΈΡΠΌΠΈ. ΠΡΠΎΡ ΡΠ΅Π½ΠΎΠΌΠ΅Π½ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ΅ΡΡΡ ΡΠ΅ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΡΠ²ΠΎΠΉΡΡΠ²Π°ΠΌΠΈ Π»ΠΈΠΌΡΡ ΠΈ ΡΡΠ΅ΠΏΠ΅Π½ΡΡ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠΉ ΡΠΎΡΡΠΎΡΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ ΡΠ΅Π³ΠΈΠΎΠ½Π°ΡΠ½ΠΎΠΉ ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ